Tag Archive for: IND

TECregen Strengthens Management Team and Board to Advance Thymus Regeneration and Lead Program TEC001

Elisabeth Svanberg, MD, PhD, appointed Chief Medical Officer, adding extensive global clinical–development and regulatory expertise Thomas Hanke, PhD, joins the Board, bringing more than 30 years of immunology, drug–discovery, and R&D experience Appointments strengthen TECregen as it advances TEC001 toward clinical development Basel, Switzerland, November 10, 2026 – TECregen, a biotechnology company pioneering thymus regeneration […]

Link Biologics completes IND-enabling preclinical programme for LB001, a first-in-class novel therapy for dry eye disease

Completion of key IND-enabling activities represents a major development milestone for LB001 IND submission remains on track for Q1 2027, followed by initiation of a Phase 1/2 clinical study Manufacturing scale-up completed, providing supply for planned clinical studies London, UK – 5 November 2026 – Link Biologics (“Link” or “the Company”), the biotech developing first-in-class […]

Hansa Biopharma announces submission of IND Application to US FDA for HNSA-5487 in GBS

The IND submission marks an important milestone in advancing Hansa’s novel IgG-cleaving enzyme into clinical development in GBS. Lund, Sweden, October 20, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that it has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for HNSA-5487, Hansa’s novel IgG-cleaving […]

Currus Biologics announces FDA IND clearance for Phase 1 trial of CUR-001 in mesothelin-positive advanced refractory solid tumours

The first clinical programme from Currus’ BEAT platform, designed to overcome the barriers that have limited CAR T-cell therapy in solid tumours CUR-001 combines CURB-001, Currus’ BEAT bispecific antibody, with CURT-001, its FLAG-tagged autologous anti-mesothelin CAR T-cell therapy The open-label basket study will enrol patients with mesothelin-positive advanced refractory solid tumours, with the first patient […]

Nucleome Therapeutics nominates first preclinical development candidate

First-in-class monoclonal antibody agonist programme for inflammation resolution with broad applicability across major chronic inflammatory diseases Evolution of Nucleome’s non-coding genetics platform reveals further groundbreaking insights into disease areas of high unmet need Oxford, UK, 07 January 2026 – Nucleome Therapeutics (‘Nucleome’ or ‘the Company’), a company tackling the molecular causes of inflammatory diseases through […]

© Optimum Strategic Communications.